<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39223870</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1463-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Diabetes, obesity &amp; metabolism</Title><ISOAbbreviation>Diabetes Obes Metab</ISOAbbreviation></Journal><ArticleTitle>Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID-19: Up to 40&#x2009;months' follow-up.</ArticleTitle><Pagination><StartPage>5368</StartPage><EndPage>5375</EndPage><MedlinePgn>5368-5375</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/dom.15900</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim was to investigate whether COVID-19 increases new incidence of hypertension (HTN), chronic kidney disease (CKD) and diabetic ketoacidosis (DKA) in patients with type 1 diabetes (T1D) up to 40 months post-infection.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Three groups of patients from the Montefiore Health System in the Bronx (1 March 2020 to 1 July 2023) were studied: T1D patients hospitalized for COVID-19 (H-COVID-19, n&#x2009;=&#x2009;511), T1D patients with COVID-19 but not hospitalized for COVID-19 (NH-COVID-19, n&#x2009;=&#x2009;306) and T1D patients without a positive COVID-19 test on record (non-COVID-19, n&#x2009;=&#x2009;1547). COVID-19 patients were those with a positive polymerase-chain-reaction test on record, and non-COVID-19 patients were either tested negative or not tested on record. Cumulative incidences and adjusted hazard ratios (aHR) with 95% confidence intervals (CI) were computed with adjustment for competing risks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to non-COVID-19 patients, both H-COVID-19 (unadjusted 19.72% vs. 3.14%, p&#x2009;&lt;&#x2009;0.001; aHR&#x2009;=&#x2009;7.55 [3.33, 17.06], p&#x2009;&lt;&#x2009;0.001) and NH-COVID-19 (10.26% vs. 3.14%, p&#x2009;=&#x2009;0.004; aHR&#x2009;=&#x2009;5.08 [2.19, 11.78], p&#x2009;&lt;&#x2009;0.001) patients were more likely to develop new HTN. Compared to non-COVID-19 patients, both H-COVID-19 (11.41% vs. 1.14%, p&#x2009;&lt;&#x2009;0.001; aHR&#x2009;=&#x2009;9.76 [4.248, 22.25], p&#x2009;&lt;&#x2009;0.001) and NH-COVID-19 (7.69% vs. 1.14%, p&#x2009;&lt;&#x2009;0.001; aHR&#x2009;=&#x2009;6.54 [2.91, 14.67], p&#x2009;&lt;&#x2009;0.001) patients were more likely to develop new CKD. Compared to non-COVID-19 patients, both H-COVID-19 (4.09% vs. 1.06%, p&#x2009;&lt;&#x2009;0.001; aHR&#x2009;=&#x2009;12.24 [4.09, 36.59], p&#x2009;&lt;&#x2009;0.001) and NH-COVID-19 (3.06% vs. 1.06%, p&#x2009;=&#x2009;0.035; aHR&#x2009;=&#x2009;12.94 [4.09, 40.89], p&#x2009;&lt;&#x2009;0.001) patients were more likely to develop new DKA at follow-up.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">T1D patients with COVID-19 are at higher risk of developing new HTN, CKD and DKA compared to T1D patients without COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2024 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mehrotra-Varma</LastName><ForeName>Shiv</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0001-0748-3514</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Centre, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Justin Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Centre, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boparai</LastName><ForeName>Montek Singh</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Centre, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Sonya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Centre, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Stephen H</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-6212-2906</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Centre, New York City, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Beth Israel Deaconess Medical Centre and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Tim Q</ForeName><Initials>TQ</Initials><Identifier Source="ORCID">0000-0001-6403-2827</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Centre, New York City, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Diabetes Obes Metab</MedlineTA><NlmUniqueID>100883645</NlmUniqueID><ISSNLinking>1462-8902</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016883" MajorTopicYN="Y">Diabetic Ketoacidosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute kidney injury</Keyword><Keyword MajorTopicYN="N">cytokine storm</Keyword><Keyword MajorTopicYN="N">diabetic ketoacidosis</Keyword><Keyword MajorTopicYN="N">high blood pressure</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">type 1 diabetes mellitus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>2</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39223870</ArticleId><ArticleId IdType="doi">10.1111/dom.15900</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID&#x2010;19&#x2010;related mortality in England: a whole&#x2010;population study. Lancet Diabetes Endocrinol. 2020;8(10):813&#x2010;822.</Citation></Reference><Reference><Citation>Demirci I, Haymana C, Tasci I, et al. Higher rate of COVID&#x2010;19 mortality in patients with type 1 than type 2 diabetes: a nationwide study. Endokrynol pol. 2022;73(1):87&#x2010;95.</Citation></Reference><Reference><Citation>Iughetti L, Trevisani V, Cattini U, et al. COVID&#x2010;19 and type 1 diabetes: concerns and challenges. Acta Biomed. 2020;91(3):e2020033.</Citation></Reference><Reference><Citation>Kristofi R, Bodegard J, Ritsinger V, et al. Patients with type 1 and type 2 diabetes hospitalized with COVID&#x2010;19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data. Cardiovasc Diabetol. 2022;21(1):282.</Citation></Reference><Reference><Citation>Nassar M, Nso N, Baraka B, et al. The association between COVID&#x2010;19 and type 1 diabetes mellitus: a systematic review. Diabetes Metab Syndr. 2021;15(1):447&#x2010;454.</Citation></Reference><Reference><Citation>Boparai MS, Musheyev B, Khan U, et al. Cardiac magnetic resonance imaging of COVID&#x2010;19&#x2010;associated cardiac sequelae: a systematic review. Rev Cardiovasc Med. 2022;23(12):389.</Citation></Reference><Reference><Citation>Lam KW, Chow KW, Vo J, et al. Continued in&#x2010;hospital angiotensin&#x2010;converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID&#x2010;19 patients is associated with positive clinical outcome. J Infect Dis. 2020;222(8):1256&#x2010;1264.</Citation></Reference><Reference><Citation>Lu JQ, Lu JY, Wang W, et al. Clinical predictors of acute cardiac injury and normalization of troponin after hospital discharge from COVID&#x2010;19. EBioMedicine. 2022;76:103821.</Citation></Reference><Reference><Citation>Su S, Hu W, Chen X, et al. Cardiac injury progression in children with multisystem inflammatory syndrome associated with SARS&#x2010;CoV&#x2010;2 infection: a review. Front Pediatr. 2024;12:1348016.</Citation></Reference><Reference><Citation>Tangos M, Jarkas M, Akin I, El&#x2010;Battrawy I, Hamdani N. Cardiac damage and tropism of severe acute respiratory syndrome coronavirus 2. Curr Opin Microbiol. 2024;78:102437.</Citation></Reference><Reference><Citation>Batlle D, Soler MJ, Sparks MA, et al. Acute kidney injury in COVID&#x2010;19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol. 2020;31(7):1380&#x2010;1383.</Citation></Reference><Reference><Citation>Chan L, Chaudhary K, Saha A, et al. AKI in hospitalized patients with COVID&#x2010;19. J Am Soc Nephrol. 2021;32(1):151&#x2010;160.</Citation></Reference><Reference><Citation>Hamilton P, Hanumapura P, Castelino L, et al. Characteristics and outcomes of hospitalised patients with acute kidney injury and COVID&#x2010;19. PLoS One. 2020;15(11):e0241544.</Citation></Reference><Reference><Citation>Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID&#x2010;19. Kidney Int. 2020;98(1):209&#x2010;218.</Citation></Reference><Reference><Citation>Lu JY, Babatsikos I, Fisher MC, Hou W, Duong TQ. Longitudinal clinical profiles of hospital vs. community&#x2010;acquired acute kidney injury in COVID&#x2010;19. Front Med (Lausanne). 2021;8:647023.</Citation></Reference><Reference><Citation>Lu JY, Boparai MS, Shi C, et al. Long&#x2010;term outcomes of COVID&#x2010;19 survivors with hospital AKI: association with time to recovery from AKI. Nephrol Dial Transplant. 2023;38(10):2160&#x2010;2169.</Citation></Reference><Reference><Citation>Lu JY, Buczek A, Fleysher R, et al. Outcomes of hospitalized patients with COVID&#x2010;19 with acute kidney injury and acute cardiac injury. Front Cardiovasc Med. 2021;8:798897.</Citation></Reference><Reference><Citation>Ouyang L, Gong Y, Zhu Y, Gong J. Association of acute kidney injury with the severity and mortality of SARS&#x2010;CoV&#x2010;2 infection: a meta&#x2010;analysis. Am J Emerg Med. 2021;43:149&#x2010;157.</Citation></Reference><Reference><Citation>Russo E, Esposito P, Taramasso L, et al. Kidney disease and all&#x2010;cause mortality in patients with COVID&#x2010;19 hospitalized in Genoa, Northern Italy. J Nephrol. 2021;34(1):173&#x2010;183.</Citation></Reference><Reference><Citation>Trabulus S, Karaca C, Balkan II, et al. Kidney function on admission predicts in&#x2010;hospital mortality in COVID&#x2010;19. PLoS One. 2020;15(9):e0238680.</Citation></Reference><Reference><Citation>Gupta A, Duggal R. Incidence of new&#x2010;onset hypertension and new&#x2010;onset type 2 diabetes during or after SARS&#x2010;CoV&#x2010;2 infection. J Assoc Physicians India. 2023;71(10):78&#x2010;82.</Citation></Reference><Reference><Citation>Zuin M, Rigatelli G, Bilato C, Pasquetto G, Mazza A. Risk of incident new&#x2010;onset arterial hypertension after COVID&#x2010;19 recovery: a systematic review and meta&#x2010;analysis. High Blood Press Cardiovasc Prev. 2023;30(3):227&#x2010;233.</Citation></Reference><Reference><Citation>Zhang V, Fisher M, Hou W, Zhang L, Duong TQ. Incidence of new&#x2010;onset hypertension post&#x2010;COVID&#x2010;19: comparison with influenza. Hypertension. 2023;80(10):2135&#x2010;2148.</Citation></Reference><Reference><Citation>Huang W, Li B, Jiang N, et al. Impact of the COVID&#x2010;19 pandemic on patients with chronic kidney disease: a narrative review. Medicine (Baltimore). 2022;101(24):e29362.</Citation></Reference><Reference><Citation>Jiang W, Chen Y, Zhao Y, et al. COVID&#x2010;19 and chronic kidney disease: a bibliometric analysis. Ann Med Surg (Lond). 2024;86(1):336&#x2010;344.</Citation></Reference><Reference><Citation>Schiffl H, Lang SM. Long&#x2010;term interplay between COVID&#x2010;19 and chronic kidney disease. Int Urol Nephrol. 2023;55(8):1977&#x2010;1984.</Citation></Reference><Reference><Citation>Dell'Aquila K, Lee J, Wang SH, et al. Incidence, characteristics, risk factors and outcomes of diabetic ketoacidosis in COVID&#x2010;19 patients: comparison with influenza and pre&#x2010;pandemic data. Diabetes Obes Metab. 2023;25(9):2482&#x2010;2494.</Citation></Reference><Reference><Citation>Rugg&#x2010;Gunn CEM, Dixon E, Jorgensen AL, et al. Factors associated with diabetic ketoacidosis at onset of type 1 diabetes among pediatric patients: a systematic review. JAMA Pediatr. 2022;176(12):1248&#x2010;1259.</Citation></Reference><Reference><Citation>Alamuri TT, Mahesh S, Dell'Aquila K, Leong TJ, Jennings R, Duong TQ. COVID&#x2010;19 associated ketosis and diabetic ketoacidosis: a rapid review. Diabetes Obes Metab. 2023;25(7):1785&#x2010;1793.</Citation></Reference><Reference><Citation>Nindenshuti PM, Caire&#x2010;Juvera G. Changes in diet, physical activity, alcohol consumption, and tobacco use in adults during the COVID&#x2010;19 pandemic: a systematic review. Inquiry. 2023;60:469580231175780.</Citation></Reference><Reference><Citation>Nour TY, Altintas KH. Effect of the COVID&#x2010;19 pandemic on obesity and it is risk factors: a systematic review. BMC Public Health. 2023;23(1):1018.</Citation></Reference><Reference><Citation>Pal J, Sethi D, Taywade M, Pal R. Role of nutrition and diet during COVID&#x2010;19 pandemic: a narrative review. J Family Med Prim Care. 2022;11(9):4942&#x2010;4948.</Citation></Reference><Reference><Citation>Tholla TS, Sawicki CM, Bhupathiraju SN. The intersection between COVID&#x2010;19, cardiovascular disease, and diet: a review. Curr Atheroscler Rep. 2023;25(10):643&#x2010;652.</Citation></Reference><Reference><Citation>Vasile CM, Padovani P, Rujinski SD, et al. The increase in childhood obesity and its association with hypertension during pandemics. J Clin Med. 2023;12(18):5909.</Citation></Reference><Reference><Citation>Hoogenboom WS, Pham A, Anand H, et al. Clinical characteristics of the first and second COVID&#x2010;19 waves in the Bronx, New York: a retrospective cohort study. Lancet Reg Health Am. 2021;3:100041.</Citation></Reference><Reference><Citation>Flores M, Amir M, Ahmed R, et al. Causes of diabetic ketoacidosis among adults with type 1 diabetes mellitus: insulin pump users and non&#x2010;users. BMJ Open Diabetes Res Care. 2020;8(2):e001329.</Citation></Reference><Reference><Citation>Maahs DM, Kinney GL, Wadwa P, et al. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005;28(2):301&#x2010;306.</Citation></Reference><Reference><Citation>Piscitelli P, Viazzi F, Fioretto P, et al. Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD annals initiative. Sci Rep. 2017;7(1):3313.</Citation></Reference><Reference><Citation>Hoffmann M, Kleine&#x2010;Weber H, Schroeder S, et al. SARS&#x2010;CoV&#x2010;2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271&#x2010;280.e278.</Citation></Reference><Reference><Citation>Maranduca MA, Vamesu CG, Tanase DM, et al. The RAAS axis and SARS&#x2010;CoV&#x2010;2: from oral to systemic manifestations. Medicina (Kaunas). 2022;58(12):1717.</Citation></Reference><Reference><Citation>Ranjbar T, Oza PP, Kashfi K. The renin&#x2010;angiotensin&#x2010;aldosterone system, nitric oxide, and hydrogen sulfide at the crossroads of hypertension and COVID&#x2010;19: racial disparities and outcomes. Int J Mol Sci. 2022;23(22):13895.</Citation></Reference><Reference><Citation>Shi S, Qin M, Cai Y, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020;41(22):2070&#x2010;2079.</Citation></Reference><Reference><Citation>Shi S, Qin M, Shen B, et al. Association of Cardiac Injury with Mortality in hospitalized patients with COVID&#x2010;19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802&#x2010;810.</Citation></Reference><Reference><Citation>Gouni&#x2010;Berthold I, Krone W. Diabetic ketoacidosis and hyperosmolar hyperglycemic state. Med Klin (Munich). 2006;101(Suppl 1):100&#x2010;105.</Citation></Reference><Reference><Citation>Dogra S, Ardern CI, Baker J. The relationship between age of asthma onset and cardiovascular disease in Canadians. J Asthma. 2007;44(10):849&#x2010;854.</Citation></Reference><Reference><Citation>Jankowski J, Floege J, Fliser D, Bohm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157&#x2010;1172.</Citation></Reference><Reference><Citation>Jiang SZ, Lu W, Zong XF, Ruan HY, Liu Y. Obesity and hypertension. Exp Ther Med. 2016;12(4):2395&#x2010;2399.</Citation></Reference><Reference><Citation>Kjeldsen SE. Hypertension and cardiovascular risk: general aspects. Pharmacol Res. 2018;129:95&#x2010;99.</Citation></Reference><Reference><Citation>Kovesdy CP, Furth S, Zoccali C, World Kidney Day Steering C. Obesity and kidney disease: hidden consequences of the epidemic. Indian J Nephrol. 2017;27(2):85&#x2010;92.</Citation></Reference><Reference><Citation>Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon&#x2010;Moran D. Hypertension prevalence and control among adults: United States, 2015&#x2010;2016. NCHS Data Brief. 2017;289:1&#x2010;8.</Citation></Reference><Reference><Citation>Hosseinpanah F, Kasraei F, Nassiri AA, Azizi F. High prevalence of chronic kidney disease in Iran: a large population&#x2010;based study. BMC Public Health. 2009;9:44.</Citation></Reference><Reference><Citation>Pinto E. Blood pressure and ageing. Postgrad Med J. 2007;83(976):109&#x2010;114.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>